FDA Approves First PROTAC Drug for Breast Cancer
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Vepdegestrant was approved by the FDA in May — the first PROTAC drug ever greenlit — after trials showed patients with advanced, spreading breast cancer survived more than twice as long as those on a conventional therapy.
- PROTACs work by slapping a ubiquitin "recycle me" tag on a target protein, sending it to the cell's proteasome for destruction; one molecule can eliminate tens to hundreds of target proteins, and PROTACs don't need to bind to the protein's active site.
- Craig Crews and Raymond Deshaies conceived the PROTAC concept at a 1998 conference; Crews founded Arvinas in 2013 and told the source his creations are "large small-molecules" — bigger than conventional pills but small enough to behave like them.
- Arvinas initially played it safe by targeting oestrogen receptors in breast cancer rather than undruggable proteins, because cancers often develop resistance by overproducing receptors — a problem degradation sidesteps entirely.
- Johnson & Johnson acquired Arvinas's "riptacs" technology after an early prostate cancer trial showed strong results; riptacs link a cancer-abundant protein to a protein essential for cell survival, killing malignant cells.
- Targeted protein degradation is booming — roughly 100 companies and around 80 trials are now in the space, and Crews says a PROTAC can degrade half of a cell's protein population within 2 hours.
- Crews calls the FDA approval "a milestone for the field" and expects it to accelerate efforts to finally crack proteins long considered undruggable by conventional small-molecule drugs and antibodies alike.
Why it matters: The FDA's approval of vepdegestrant validates an entirely new therapeutic modality that works through destruction rather than inhibition — making thousands of previously "undruggable" protein targets potentially treatable. Treatment-resistant breast cancer patients are the first beneficiaries, but with ~100 companies and ~80 trials now pursuing PROTAC-based drugs, the approval opens a pipeline that could reshape drug development across oncology and beyond.
